Revolution Medicines (RVMD) EPS (Weighted Average and Diluted) (2020 - 2026)
Revolution Medicines (RVMD) recorded quarterly EPS (Weighted Average and Diluted) of -$2.29 in Q1 2026, down 21.16% quarter-over-quarter from -$1.89 in Q4 2025, and down 102.65% on a YoY basis from $86.26 in Q1 2025.
Revolution Medicines (RVMD) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Revolution Medicines' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$2.29 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 102.65% year-over-year to -$2.29; the TTM figure through Mar 2026 stood at -$7.1 (down 77.06% YoY), while the FY2025 annual figure was -$5.95, down 66.2% from the prior year.
- EPS (Weighted Average and Diluted) was -$2.29 for Q1 2026 at Revolution Medicines, down from -$1.89 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.61 in Q4 2022 to a low of -$2.29 in Q1 2026.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.1 across 5 years, with a median of -$0.94 in 2024.
- The sharpest annual moves came in 2022 and 2026: EPS (Weighted Average and Diluted) advanced 15.28% in 2022, then plunged 102.65% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.61 in 2022, then tumbled by 98.36% to -$1.21 in 2023, then gained by 6.61% to -$1.13 in 2024, then tumbled by 67.26% to -$1.89 in 2025, then declined by 21.16% to -$2.29 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$2.29 (Q1 2026), -$1.89 (Q4 2025), and -$1.61 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Revolution Medicines | 32.33 Bn | 32.33 Bn | - | -2.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.29 |
| Dec 31, 2025 | -1.89 |
| Sep 30, 2025 | -1.61 |
| Jun 30, 2025 | -1.31 |
| Mar 31, 2025 | -1.13 |
| Dec 31, 2024 | -1.13 |
| Sep 30, 2024 | -0.94 |
| Jun 30, 2024 | -0.81 |
| Mar 31, 2024 | -0.70 |
| Dec 31, 2023 | -1.21 |
| Sep 30, 2023 | -0.99 |
| Jun 30, 2023 | -0.92 |
| Mar 31, 2023 | -0.72 |
| Dec 31, 2022 | -0.61 |
| Sep 30, 2022 | -0.87 |
| Jun 30, 2022 | -0.82 |
| Mar 31, 2022 | -0.78 |
| Dec 31, 2021 | -0.72 |
| Sep 30, 2021 | -0.72 |
| Jun 30, 2021 | -0.60 |